• PF-573228: FAK Inhibitor Evidence & Workflow

  2026-09-18

  PF-573228 is an ATP-competitive FAK inhibitor with a reported biochemical IC50 of 4 nM. Evidence supports its use for dissecting FAK phosphorylation, cancer cell migration, endothelial responses, and FAK/MAPK/ERK signaling in experimental models.

• Tin Mesoporphyrin IX: HO Inhibition Guide

  2026-09-18

  Tin Mesoporphyrin IX (chloride) is a competitive heme oxygenase inhibitor with a reported in vitro Ki of 14 nM against rat splenic microsomal heme oxygenase. Its strongest research value is as a mechanistic tool for heme catabolism, metabolic disease research, and carefully controlled HO-linked redox studies rather than as a clinical or established antiviral treatment.

• RapaLink-1: Designing Better mTOR Assays

  2026-09-17

  RapaLink-1 is a third-generation mTOR inhibitor that enables more discriminating studies of mTORC1 inhibition, resistant signaling, and phenotype. This article develops an assay-design framework linking its bivalent pharmacology to insights from reversible embryonic dormancy models.

• Caged Bioluminescent Probe for Immunoproteasome

  2026-09-17

  Loy and Trader describe a cleavable, bioluminescent activity-based probe designed to report immunoproteasome activity, with emphasis on the β5i-containing isoform. The synthesis and plate-reader workflow offers a practical route for studying immunoproteasome function in cellular systems and tissue-mimicking conditions, while the authors identify in vivo translation as an important next step.

• NBC19: Linking Inflammasome Assays to CAML Biology

  2026-09-16

  NBC19, a potent NLRP3 inflammasome inhibitor, offers a precise way to test how inflammatory signaling may intersect with circulating cancer-associated macrophage-like cells. This article translates CAML phenotyping insights into better assay design while clearly separating established evidence from testable hypotheses.

• Tyrothricin: Applied Antimicrobial Workflows

  2026-09-16

  Tyrothricin is a peptide antibiotic mixture suited to rapid, mechanism-focused studies of microbial membrane injury across bacteria and selected nonbacterial models. This guide translates the product’s membrane-disruption profile and a redox-biology reference study into practical assay design, controls, and troubleshooting steps.

• ER-Targeting Peptide Self-Assembly in Cancer Cells

  2026-09-15

  The reference study develops an alkaline-phosphatase-triggered peptide that self-assembles at the endoplasmic reticulum through a p-toluenesulfonamide targeting group. This design selectively increases ER stress and cancer-cell death while reducing the concentration dependence of earlier intracellular enzyme-instructed self-assembly strategies.

• CGP 55845 Hydrochloride in GABAB Assays

  2026-09-14

  Use CGP 55845 hydrochloride as a receptor-level control when separating GABAB signaling from astrocytic GAT-3 effects in dentate gyrus experiments. This practical guide connects antagonist pharmacology with whole-cell recording, calcium imaging, optogenetics, and neurotransmitter release modulation while emphasizing in vitro interpretation limits.

• Moxifloxacin: From Gyrase Traps to Toxicity Models

  2026-09-14

  Moxifloxacin is a fluoroquinolone antibiotic that connects bacterial DNA-gyrase pharmacology with cellular and metabolic toxicity research. This guide presents a target-engagement framework for selecting assays, interpreting retinal-cell findings, and controlling compound handling.

• Dehydroepiandrosterone (DHEA) Research Workflows

  2026-09-13

  Dehydroepiandrosterone (DHEA) supports two distinct research strategies: endocrine challenge modeling in ovarian biology and concentration-controlled studies of neural survival. This practical guide connects formulation, assay design, and troubleshooting with the mitochondrial steroidogenesis findings reported in a recent PCOS study.

• Prednisone as a Translational Immunology Benchmark

  2026-09-12

  Prednisone offers translational researchers a defined synthetic corticosteroid benchmark for studying lymphocyte cell-cycle control, IL-2 signaling, apoptosis, formulation variables, and the limits of connecting immune assays with neurodegeneration models.

• BV6: Reframing IAP Antagonism for Translation

  2026-09-11

  BV6 is a Smac-mimetic IAP antagonist that provides a mechanistically tractable way to study apoptosis, treatment sensitization, and disease-model biology. This thought-leadership analysis connects IAP-dependent survival signaling with RIPK3–MLKL pathway resolution, offering translational researchers a strategy for stronger experimental design without overstating preclinical evidence.

• Cefepime (BMY-28142) in CNS Infection Models

  2026-09-11

  Explore how Cefepime (BMY-28142) can support central nervous system infection research through mechanism-informed antibacterial, barrier-transport, and neurotoxicity assays. This guide translates cephalosporin PK/PD principles into practical experimental decisions without conflating cefepime with newer comparator antibiotics.

• Plerixafor (AMD3100): Assay Reliability Guide

  2026-09-10

  A scenario-based guide to using Plerixafor (AMD3100), SKU A2025, in CXCR4 signaling, migration, viability, and mobilization studies. It connects formulation, controls, quantitative potency data, and interpretation strategies to help laboratories reduce assay ambiguity and improve experimental comparability.

• Mitoxantrone Workflows for ABCG2 Resistance

  2026-09-10

  Build reproducible Mitoxantrone assays for DNA-damage response, apoptosis, and transporter-mediated drug resistance. This guide connects controlled DMSO handling with ABCG2 accumulation studies and marein combination experiments, while separating oncology applications from early anti-orthopoxvirus research.

8535 records 1/569 page Next 12345 下5页 Last page